Esperion Therapeutics (ESPR) Current Assets (2012 - 2026)

Esperion Therapeutics' Current Assets history runs 15 years deep, the most recent figure standing at $459.5 million for Q1 2026.

• Quarterly Current Assets rose 44.13% year-over-year to $459.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $459.5 million (up 44.13% YoY) and the FY2025 annual result came in at $462.6 million, up 36.86% from the prior year.
• Current Assets was $459.5 million for Q1 2026 at Esperion Therapeutics, down from $462.6 million in the prior quarter.
• Across five years, Current Assets topped out at $462.6 million in Q4 2025 and bottomed at $201.1 million in Q4 2023.
• A 5-year average of $309.1 million and a median of $307.6 million in 2024 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2022 — Current Assets retreated 25.01% — and 2024, when it surged 68.1%.
• Esperion Therapeutics' Current Assets stood at $246.7 million in 2022, then decreased by 18.49% to $201.1 million in 2023, then jumped by 68.1% to $338.0 million in 2024, then jumped by 36.86% to $462.6 million in 2025, then fell by 0.67% to $459.5 million in 2026.
• Business Quant data shows ESPR's Current Assets at $459.5 million in Q1 2026, $462.6 million in Q4 2025, and $360.5 million in Q3 2025.